Melissa Lumish

Melissa Lumish

Auto-generated profile, based on publicly available information

Melissa Lumish

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
ACAndrea Cercek
Andrea Cercek
MLMelissa Lumish
Melissa Lumish
JSJenna Sinopoli
Jenna Sinopoli
JWJill Weiss
Jill Weiss
JSJinru Shia
Jinru Shia
LDLuis A. Diaz
Luis A. Diaz
Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

19 June 2025 in New England Journal of Medicine
Verified
Journal Article
Open access
ACAndrea Cercek
Andrea Cercek
MFMichael B. Foote
Michael B. Foote
BRBenoit Rousseau
Benoit Rousseau
JSJ. Joshua Smith
J. Joshua Smith
JSJinru Shia
Jinru Shia
LDLuis A. Diaz
Luis A. Diaz
Among patients with mismatch repair-deficient (dMMR), locally advanced rectal cancer, neoadjuvant checkpoint blockade eliminated the need for surgery in a high proportion of patients. Whether this approach can be extended to all early-stage dMMR solid tumors, regardless of tumor site, is unknown. We conducted a phase 2 study in which patients with stage I, II, or III dMMR solid tumors that were amenable to curative-intent surgery were treated with neoadjuvant dostarlimab, a programmed cell death 1 (PD-1) blocking agent, for 6 months. The response to treatment was assessed in two cohorts: patients in cohort 1 had dMMR, locally advanced rectal cancer, and patients in cohort 2 had dMMR nonrectal solid tumors. Patients with a clinical complete response could elect to proceed with nonoperative management; those with residual disease were to undergo resection. In this analysis, the primary end point, assessed in cohort 1, was a sustained clinical complete response at 12 months. Recurrence-free survival and safety were evaluated. A total of 117 patients were included in the analysis. In cohort 1, all 49 patients who completed treatment had a clinical complete response and elected to proceed with nonoperative management. A total of 37 patients had a sustained clinical complete response at 12 months, a finding that met the criterion for efficacy. In cohort 2, a total of 35 of 54 patients who completed treatment had a clinical complete response, and 33 elected to proceed with nonoperative management. Among the 103 patients who completed treatment across both cohorts, 84 had a clinical complete response, and 82 did not undergo surgery. Among the 117 total patients, recurrence-free survival at 2 years was 92% (95% confidence interval, 86 to 99); the median follow-up for recurrence was 20.0 months (range, 0 to 60.8). The majority of patients (95%) had reversible, grade 1 or 2 adverse events (60%) or had no adverse events (35%). The option for curative resection was not compromised during or after treatment in any of the patients. Among patients with early-stage dMMR solid tumors that were amenable to curative-intent surgery, neoadjuvant PD-1 blockade led to organ preservation in a high proportion of patients. (Funded by Swim Across America and others; ClinicalTrials.gov number, NCT04165772.).

30 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
AMAndrew Moorman
Andrew Moorman
EBElizabeth K. Benitez
Elizabeth K. Benitez
FCFrancesco Cambulli
Francesco Cambulli
QJQingwen Jiang
Qingwen Jiang
AMAhmed Mahmoud
Ahmed Mahmoud
KGKaruna Ganesh
Karuna Ganesh
As cancers progress, they become increasingly aggressive—metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire resistance to successive therapies and eventually cause death1,2. Mutations are largely conserved between primary and metastatic tumours from the same patients, suggesting that non-genetic phenotypic plasticity has a major role in cancer progression and therapy resistance3–5. However, we lack an understanding of metastatic cell states and the mechanisms by which they transition. Here, in a cohort of biospecimen trios from same-patient normal colon, primary and metastatic colorectal cancer, we show that, although primary tumours largely adopt LGR5+ intestinal stem-like states, metastases display progressive plasticity. Cancer cells lose intestinal cell identities and reprogram into a highly conserved fetal progenitor state before undergoing non-canonical differentiation into divergent squamous and neuroendocrine-like states, a process that is exacerbated in metastasis and by chemotherapy and is associated with poor patient survival. Using matched patient-derived organoids, we demonstrate that metastatic cells exhibit greater cell-autonomous multilineage differentiation potential in response to microenvironment cues compared with their intestinal lineage-restricted primary tumour counterparts. We identify PROX1 as a repressor of non-intestinal lineage in the fetal progenitor state, and show that downregulation of PROX1 licenses non-canonical reprogramming.

20 October 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JJJustin Jee
Justin Jee
MFMichael B. Foote
Michael B. Foote
MLMelissa Lumish
Melissa Lumish
ASAaron J. Stonestrom
Aaron J. Stonestrom
BWBeatriz Wills
Beatriz Wills
MPMelissa S. Pessin
Melissa S. Pessin
PURPOSE: Coronavirus-2019 (COVID-19) mortality is higher in patients with cancer than in the general population, yet the cancer-associated risk factors for COVID-19 adverse outcomes are not fully characterized.PATIENTS AND METHODS: We reviewed clinical characteristics and outcomes from patients with cancer and concurrent COVID-19 at Memorial Sloan Kettering Cancer Center until March 31, 2020 (n = 309), and observed clinical end points until April 13, 2020. We hypothesized that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. In secondary analyses, we estimated associations between specific clinical and laboratory variables and the incidence of a severe or critical COVID-19 event.RESULTS: Cytotoxic chemotherapy administration was not significantly associated with a severe or critical COVID-19 event (HR, 1.10; 95% CI, 0.73 to 1.60). Hematologic malignancy was associated with increased COVID-19 severity (HR, 1.90; 95% CI, 1.30 to 2.80). Patients with lung cancer also demonstrated higher rates of severe or critical COVID-19 events (HR, 2.0; 95% CI, 1.20 to 3.30). Lymphopenia at COVID-19 diagnosis was associated with higher rates of severe or critical illness (HR, 2.10; 95% CI, 1.50 to 3.10). Patients with baseline neutropenia 14-90 days before COVID-19 diagnosis had worse outcomes (HR, 4.20; 95% CI, 1.70 to 11.00). Findings from these analyses remained consistent in a multivariable model and in multiple sensitivity analyses. The rate of adverse events was lower in a time-matched population of patients with cancer without COVID-19.CONCLUSION: Recent cytotoxic chemotherapy treatment was not associated with adverse COVID-19 outcomes. Patients with active hematologic or lung malignancies, peri–COVID-19 lymphopenia, or baseline neutropenia had worse COVID-19 outcomes. Interactions among antineoplastic therapy, cancer type, and COVID-19 are complex and warrant further investigation.

12 September 2023 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
MLMelissa A Lumish
Melissa A Lumish
HWHenry Walch
Henry Walch
SMSteven B Maron
Steven B Maron
WCWalid Chatila
Walid Chatila
YKYelena Kemel
Yelena Kemel
ACAndrea Cercek
Andrea Cercek
The rate of esophagogastric cancer (EGC) is rising among individuals under the age of 50. It remains unknown whether early onset (EO)-EGC represents a unique entity. This study investigates the clinical and molecular characteristics of EO- and average onset (AO)-EGC. We reviewed the Memorial Sloan Kettering Cancer Center gastric, esophageal and gastroesophageal junction (GEJ) cancer database. Associations between baseline characteristics and tumor and germline molecular alterations were compared between those with EO- and AO-EGC using Fisher’s exact test, and the Benjamini-Hochberg method for multiple hypothesis correction. We included 1123 patients with EO-EGC (n = 219, median age 43, range 18-49 years) and AO-EGC (n = 904, median age 67, range 50-94 years) treated between 2005 and 2018. The EO group had more females (39% vs 28%, p = .002). Patients with EO-EGC were more likely to have a gastric primary site (64% vs 44%, p < .0001). The signet ring cell/diffuse type was three-times more common in the EO-EGC group (31% vs 9%, p < .0001). EO tumors were more frequently genomically stable (31% vs 18%, p = .0002) and unlikely to be microsatellite-instability-high (2% vs 7%, p = .003). After restricting to adenocarcinoma and signet ring cell/diffuse type carcinomas, we observed no difference in stage (p = 0. 394) or overall survival from stage IV diagnosis (median 22.7 vs 22.1 months, p = .78). Our study supports a preponderance of gastric primary disease site, signet ring histology and genomically stable molecular subtype in EO-EGC. This highlights the need for further research to define the underlying pathogenesis and strategies for early detection and prevention.

15 December 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
AEArielle Elkrief
Arielle Elkrief
NWNicholas R. Waters
Nicholas R. Waters
NSNatalie Smith
Natalie Smith
ADAngel Dai
Angel Dai
JSJohn Slingerland
John Slingerland
JPJonathan U. Peled
Jonathan U. Peled
Colitis induced by treatment with immune-checkpoint inhibitors (ICI), termed irColitis, is a substantial cause of morbidity complicating cancer treatment. We hypothesized that abnormal fecal microbiome features would be present at the time of irColitis onset and that restoring the microbiome with fecal transplant from a healthy donor would mitigate disease severity. Herein, we present fecal microbiota profiles from 18 patients with irColitis from a single center, 5 of whom were treated with healthy-donor fecal microbial transplantation (FMT). Although fecal samples collected at onset of irColitis had comparable α-diversity to that of comparator groups with gastrointestinal symptoms, irColitis was characterized by fecal microbial dysbiosis. Abundances of Proteobacteria were associated with irColitis in multivariable analyses. Five patients with irColitis refractory to steroids and biologic anti-inflammatory agents received healthy-donor FMT, with initial clinical improvement in irColitis symptoms observed in four of five patients. Two subsequently exhibited recurrence of irColitis symptoms following courses of antibiotics. Both received a second “salvage” FMT that was, again, followed by clinical improvement of irColitis. In summary, we observed distinct microbial community changes that were present at the time of irColitis onset. FMT was followed by clinical improvements in several cases of steroid- and biologic-agent-refractory irColitis. Strategies to restore or prevent microbiome dysbiosis in the context of immunotherapy toxicities should be further explored in prospective clinical trials.